Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Spoke,
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC…
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC…
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC…
GlobeNewswire 2021-07-29 Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble…
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc.